Yes it is, and insulin is hard, but antibodies are even harder, mostly to do with the manufacturing platform "CHO". Also insulin is still more expensive than it should be due to patent ever greening.
We would see prices of antibodies go down if the manufacturing could be switched to something "not CHO" but the IP landscape is locked up by a company! They will expire in 10 years or so.
